Ensuring appropriate polypharmacy: Patients with frailty or moving towards end of life care
Posted on:
PrescQIPP bulletin
This PrescQIPP bulletin focuses on frailty and end of life and the specific considerations that would apply to this group of patients when reviewing medicines or considering stopping medicines. Medicines that should usually be continued and those with increased potential to cause harm are highlighted in the full bulletin with evidence-based tools to help the review process.
PrescQIPP bulletin 153 – Polypharmacy and deprescribing
PrescQIPP briefing 153 – Polypharmacy and deprescribing